Immunostimulant therapy with levamisole for rheumatoid arthritis

Lancet. 1976 Feb 21;1(7956):393-5. doi: 10.1016/s0140-6736(76)90218-x.

Abstract

In a controlled study involving thirty-four patients levamisole was shown to be as effective as D-penicillamine and more effective than placebo in the treatment of rheumatoid arthritis. Its action was slow and was accompanied by a reduction in erythrocyte sedimentation-rate, rheumatoid factor, and technetium index. These properties indicate that it has a specific action like that of D-penicillamine. Stimulation of cell-mediated immunity was evident in patients treated with levamisole, and there was a correlation between such changes and pain relief. Animal models confirmed the absence of anti-inflammatory effect and provided some evidence of enhancement of cell-mediated immunity and macrophage stimulation.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Cell Migration Inhibition
  • Clinical Trials as Topic
  • Complement System Proteins
  • Drug Evaluation
  • Follow-Up Studies
  • Humans
  • Hypersensitivity, Delayed / diagnosis
  • Immunity, Cellular / drug effects*
  • Immunoglobulins / analysis
  • Levamisole / pharmacology
  • Levamisole / therapeutic use*
  • Male
  • Mice
  • Pain / drug therapy
  • Penicillamine / therapeutic use
  • Placebos
  • Rats
  • Skin Tests
  • Time Factors

Substances

  • Immunoglobulins
  • Placebos
  • Levamisole
  • Complement System Proteins
  • Penicillamine